Related Experiment Video
Updated: Mar 17, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Hepatitis C Viral Infection in Children: Updated Review
1Department of Pediatric Hepatology, Gastroenterology and Nutrition, National Liver Institute, Menoufiya University, Shebin El Kom, Menoufiya, Egypt.
Insights
Hepatitis C virus (HCV) infection impacts millions globally, primarily affecting the liver. Current treatments for children, like pegylated-Interferon and ribavirin, have risks, and newer direct-acting antivirals are not yet approved for pediatric use.
Area of Science:
- Hepatology
- Virology
- Pediatric Infectious Diseases
Background:
- Hepatitis C virus (HCV) infection is a significant global health issue, primarily replicating in liver hepatocytes.
- HCV infection presents diverse genotypes and transmission routes, with vertical transmission common in developed countries and horizontal in developing ones.
- Pediatric HCV infection often remains asymptomatic, with minimal initial symptoms in about 15% of cases.
Purpose of the Study:
- To review the current landscape of pediatric Hepatitis C virus (HCV) infection, including diagnosis, treatment challenges, and prevention strategies.
- To highlight the limitations of existing therapies and the unmet need for approved treatments in children and young adults.
- To identify future research directions for pediatric HCV-related diseases.
Main Methods:
- Literature review of pediatric HCV infection, focusing on epidemiology, clinical presentation, and treatment outcomes.
- Analysis of current treatment guidelines and the efficacy and adverse effects of pegylated-Interferon plus ribavirin.
- Examination of the status of direct-acting antiviral (DAA) drug approvals for pediatric populations.
Main Results:
- HCV RNA detection is key for diagnosing acute and chronic infections.
- Pegylated-Interferon plus ribavirin offers a 50-90% chance of viral clearance but carries significant adverse effects.
- Direct-acting antiviral (DAA) drugs, effective in adults, are not yet approved for individuals under 18.
Conclusions:
- Effective management of pediatric HCV requires balancing treatment benefits against adverse effects, especially given the limited approved options.
- Prevention of perinatal and parenteral transmission is crucial for mitigating HCV infection in children.
- Further research is needed to develop and approve safe and effective treatments for HCV in pediatric populations.
Abstract:
Hepatitis C virus (HCV) infection is a major medical challenge affecting around 200 million people worldwide. The main site of HCV replication is the hepatocytes of the liver. HCV is a positive enveloped RNA virus from the flaviviridae family. Six major HCV genotypes are implicated in the human infection. In developed countries the children are infected mainly through vertical transmission during deliveries, while in developing countries it is still due to horizontal transmission from adults. Minimal nonspecific and brief symptoms are initially found in approximately 15% of children. Acute and chronic HCV infection is diagnosed through the recognition of HCV RNA. The main objective for treatment of chronic HCV is to convert detected HCV viremia to below the detection limit. Children with chronic HCV infection are usually asymptomatic and rarely develop severe liver damage. Therefore, the benefits from current therapies, pegylated-Interferon plus ribavirin, must be weighed against their adverse effects. This combined treatment offers a 50-90% chance of clearing HCV infection according to several studies and on different HCV genotype. Recent direct acting antiviral (DAA) drugs which are well established for adults have not yet been approved for children and young adults below 18 years. The most important field for the prevention of HCV infection in children would be the prevention of perinatal and parenteral transmission. There are areas of focus for new lines of research in pediatric HCV-related disease that can be addressed in the near future.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...